- Home
- INMB vs ACET Comparison
INMB vs ACET Comparison
Compare INMB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ACET |
|---|---|---|
| Founded | 2015 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 69.6M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | INMB | ACET |
|---|---|---|
| Price | $1.15 | $6.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.87 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 430.5K | 86.5K |
| Earning Date | 05-07-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $0.45 |
| 52 Week High | $11.64 | $9.05 |
Technical Indicators
Market Signals| Indicator | INMB | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 39.36 |
| Support Level | N/A | $0.64 |
| Resistance Level | $1.48 | $8.34 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 1.56 | 3.82 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.